What is the recommended management of cardiac disease in pregnant women?

Management of Cardiac Disease in Pregnancy

Pregnant women with cardiac disease require management by a specialized multidisciplinary Pregnancy Heart Team, with care stratified by disease severity and risk classification, prioritizing pre-pregnancy counseling and delivery at specialized centers for high-risk patients. 1

Core Management Principles

Pre-Pregnancy Counseling and Risk Stratification

All women of childbearing age with known or suspected cardiac disease must receive counseling before pregnancy occurs 1. This is critical because:

• Cardiac disease is now the leading cause of maternal death in Western countries 1
• 0.2-4% of pregnancies are complicated by cardiovascular disease, with numbers increasing 1
• Many conditions require intervention before conception to optimize outcomes

Risk assessment should identify:

• Severe mitral stenosis (<1.5 cm²) - requires intervention pre-pregnancy 1
• Severe aortic stenosis (<1.0 cm²) with symptoms or LV dysfunction (LVEF <50%) - requires intervention pre-pregnancy 1
• Severe regurgitant lesions with symptoms, ventricular dysfunction, or dilatation - requires surgical correction pre-pregnancy 1
• Mechanical prosthetic valves - requires detailed anticoagulation planning 1

Multidisciplinary Team Structure

The Pregnancy Heart Team must include 1:

• Cardiologists with expertise in pregnancy
• Obstetricians experienced in high-risk pregnancy
• Anesthesiologists
• Neonatologists
• Clinical geneticists (when appropriate)

High-risk patients must be managed at specialized centers with expertise in both cardiac disease and pregnancy complications 1.

Disease-Specific Management

Valvular Heart Disease

Mitral Stenosis

This is particularly dangerous as hemodynamic changes of pregnancy can precipitate acute decompensation even in previously asymptomatic women 1, 2.

Medical Management:

• β1-selective blockers (metoprolol preferred) for symptoms or pulmonary hypertension - Class I recommendation 1
• Diuretics when congestive symptoms persist despite β-blockers - Class I recommendation 1
• Restrict physical activity in symptomatic patients 1

Intervention During Pregnancy:

• Percutaneous mitral commissurotomy should be considered if severe symptoms or systolic pulmonary artery pressure >50 mmHg despite medical therapy - Class IIa recommendation 1
• Perform in second trimester when possible to minimize fetal radiation exposure 2

Anticoagulation:

• Therapeutic anticoagulation required for atrial fibrillation, left atrial thrombosis, or prior embolism 1
• Immediate IV UFH followed by LMWH if AF develops 1

Aortic Stenosis

Severe AS poses significant risk during pregnancy due to fixed cardiac output and inability to meet increased hemodynamic demands 1.

Pre-pregnancy intervention required if:

• Symptomatic with severe AS - Class I 1
• LV dysfunction (LVEF <50%) - Class I 1
• Symptoms develop during exercise testing - Class I 1
• Blood pressure falls below baseline during exercise testing - Class IIa 1

Mechanical Prosthetic Valves - Anticoagulation Strategy

This represents one of the most challenging management scenarios due to competing maternal and fetal risks 1, 2.

The anticoagulation regimen depends on warfarin dose requirements:

For LOW-DOSE warfarin (<5 mg/day or phenprocoumon <3 mg/day):

• Consider continuing OACs throughout first trimester after patient information and consent - Class IIa 1
• Alternative: Discontinue OACs weeks 6-12, replace with adjusted-dose UFH (aPTT ≥2× control) or LMWH (anti-Xa 0.8-1.2 U/mL) - Class IIa 1

For HIGH-DOSE warfarin (>5 mg/day or phenprocoumon >3 mg/day):

• Discontinue OACs weeks 6-12 and replace with adjusted-dose UFH or LMWH - Class IIa 1
• UFH should be IV infusion in high-risk patients 1

Second and third trimesters (all patients):

• Resume OACs - Class I recommendation 1
• Continue until 36th week of gestation 1

At 36 weeks:

• Switch to dose-adjusted UFH (aPTT ≥2× control) or LMWH (anti-Xa 0.8-1.2 U/mL) - Class I 1
• LMWH replaced by IV UFH at least 36 hours before planned delivery 1
• UFH discontinued 4-6 hours before delivery, restarted 4-6 hours after if no bleeding 1

Critical monitoring requirements:

• Weekly anti-Xa levels for LMWH 1
• Weekly INR monitoring for OACs 1
• All anticoagulation changes must occur in hospital - Class I 1

Important caveat: LMWH should be avoided unless anti-Xa levels are monitored - Class III recommendation 1. The evidence for LMWH efficacy in mechanical valves during pregnancy is limited 1, 2.

Cardiomyopathy

Peripartum Cardiomyopathy (PPCM)

Most common cause of severe cardiac complications in pregnancy 1.

Acute Management:

• Standard heart failure therapy once fetus delivered 1
• During pregnancy: ACE inhibitors, ARBs, and renin inhibitors are contraindicated due to fetotoxicity 1
• Use hydralazine and nitrates for afterload reduction instead 1
• β1-selective blockers (metoprolol) - avoid atenolol 1
• Diuretics only if pulmonary congestion present (may decrease placental blood flow) 1
• Avoid aldosterone antagonists 1

Anticoagulation:

• Consider LMWH or OACs (depending on pregnancy stage) for reduced EF 1
• Required for intracardiac thrombus, systemic embolism, or AF with heart failure 1

Delivery:

• Vaginal delivery preferred if hemodynamically stable 1
• Urgent delivery regardless of gestation if advanced heart failure with hemodynamic instability 1

Subsequent pregnancy:

• Discourage if EF has not normalized 1
• Recurrence risk 30-50% even with normalized EF 1

Dilated Cardiomyopathy

Managed similarly to PPCM with pregnancy-specific medication modifications 1.

Venous Thromboembolism

Risk Assessment Required for All Pregnant Women - Class I 1

Prophylaxis Strategy:

High-risk patients:

• Antenatal LMWH prophylaxis - Class I 1
• Postpartum LMWH for 6 weeks - Class I 1
• Graduated compression stockings antepartum and postpartum - Class I 1

Intermediate-risk patients:

• Consider antenatal LMWH prophylaxis - Class IIa 1
• Postpartum LMWH for ≥7 days or longer if >3 risk factors persist - Class I 1
• Consider graduated compression stockings - Class IIa 1

Low-risk patients:

• Early mobilization and hydration - Class I 1

Acute VTE Treatment:

• UFH for high-risk patients - Class I 1
• LMWH for non-high-risk patients - Class I 1
• Weight-adjusted therapeutic doses, twice daily 1
• Continue for at least 3 months or 6 months if late pregnancy PE 1

Important: Routine thrombophilia screening should NOT be performed - Class III 1

Hemodynamic Monitoring During Pregnancy

Pregnancy induces profound cardiovascular changes 1:

• Increased blood volume (30-50%)
• Increased cardiac output (30-50%)
• Decreased systemic vascular resistance
• Increased heart rate
• Hypercoagulable state

Follow-up frequency depends on disease severity:

• Mild/moderate regurgitation: every trimester 1
• Severe lesions or symptoms: individualized, often monthly or more frequently 1
• Mechanical valves: frequent monitoring with weekly INR checks 1

Delivery Planning

Mode of Delivery

Vaginal delivery is preferred in most cardiac conditions unless obstetric indications for cesarean exist 1.

Cesarean delivery indicated for:

• Delivery while on OACs (emergency situation) - Class I 1
• Severe decompensated heart failure
• Acute aortic dissection
• Obstetric indications

Delivery optimization:

• Epidural anesthesia preferred for symptomatic patients 1
• Shortened second stage (assisted delivery) for symptomatic patients 1
• Close hemodynamic monitoring throughout labor and delivery 1

Timing of Delivery

• Plan delivery in advance when possible 2
• Coordinate with multidisciplinary team 1, 2
• If cardiac surgery needed during pregnancy and fetus viable, deliver first 1

Common Pitfalls and How to Avoid Them

1. Missing cardiac disease in pregnancy: Shortness of breath attributed to pregnancy rather than mitral stenosis or pulmonary hypertension 2. Solution: Maintain high index of suspicion; perform ECG and echocardiography when cardiac disease suspected.

2. Inadequate anticoagulation monitoring in mechanical valves: Variable LMWH levels and inadequate anti-Xa monitoring leading to valve thrombosis 1. Solution: Weekly anti-Xa monitoring mandatory; consider continuing OACs in first trimester for low-dose patients.

3. Using contraindicated medications: ACE inhibitors, ARBs during pregnancy causing fetotoxicity 1. Solution: Switch to hydralazine/nitrates before conception or immediately upon pregnancy diagnosis.

4. Failure to plan anticoagulation transitions: Delivery occurring while on OACs 1. Solution: Structured transition at 36 weeks to UFH/LMWH with clear timing protocols.

5. Inadequate pre-pregnancy counseling: Women with severe stenotic lesions becoming pregnant without prior intervention 1, 2. Solution: Systematic counseling for all women of childbearing age with cardiac disease.

Evidence Quality Considerations

Important limitation: Most recommendations are Level C evidence due to lack of prospective randomized trials (ethical constraints in pregnant populations) 1. However, the ESC guidelines 1 represent the most comprehensive and recent synthesis of available evidence, incorporating registry data and expert consensus where randomized data are unavailable.

The anticoagulation recommendations for mechanical valves remain particularly challenging, with the 2011 ESC guidelines 1 acknowledging that "pregnancy in a patient with a mechanical prosthesis is associated with maternal mortality between 1-4%, mainly due to valve thrombosis while on heparin therapy" 2. This underscores why continuation of OACs during first trimester may be considered for patients requiring >5 mg warfarin daily, despite embryopathy risk 1.